111 Inc. (YI.US) Subsidiary Guangdong Yihao Pharmaceutical Named Among "Top 100 Private Enterprises in Guangdong"

Stock News
Nov 27

Guangdong Yihao Pharmaceutical Co., Ltd. ("Guangdong Yihao Pharmaceutical"), a subsidiary of 111 Inc. (YI.US), has been recognized for the third consecutive year in the "2025 Top 100 Private Enterprises in Guangdong" list and ranked among the "Top 50 Private Enterprises in Guangdong" for three straight years.

Located in Guangzhou's Zengcheng District within the China Aviation Logistics Park, Guangdong Yihao Pharmaceutical operates a warehouse spanning over 26,000 square meters. Since its establishment, the company has achieved rapid growth, reporting annual revenue of RMB 3.25 billion in 2024.

As 111 Inc.'s key operational hub in South China, Guangdong Yihao Pharmaceutical drives the group's B2B pharmaceutical distribution expansion. Headquartered in Guangzhou, the company has built an efficient pharmaceutical supply chain network covering the entire country. Its product portfolio includes over 200,000 items, such as pharmaceuticals, medical devices, and health supplements. Leveraging modern warehousing infrastructure and 111 Inc.'s expertise in smart supply chains, digital marketing, and user management, the company has established an integrated online-offline pharmaceutical service network and an omnichannel digital marketing platform.

Operationally, Guangdong Yihao Pharmaceutical utilizes 111 Inc.'s R&D capabilities and digital innovation to reduce costs across information sharing, collaboration, warehousing, and logistics. As a strategic hub in South China, the company remains committed to advancing digital technology and enhancing customer experience while empowering industry partners through smart supply chain solutions to accelerate the sector's digital transformation.

Founded in 2010, 111 Inc. has developed an integrated healthcare ecosystem comprising its online pharmacy "111.com," offline stores, telemedicine platform "1 Clinic," digital pharmaceutical distribution service "1 Drug Mall," and SaaS-based "1 Health." The company maintains direct procurement partnerships with over 500 global pharmaceutical manufacturers. Its B2B platform "1 Drug Mall" serves more than 500,000 independent and small-chain pharmacies, covering approximately 90% of China's retail pharmacy market.

111 Inc. became the first Chinese internet healthcare company to list on Nasdaq (ticker: YI) on September 12, 2018.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10